Skip to content
Study details
Enrolling now

Trial of a Harm Reduction Strategy for People With HIV Who Smoke Cigarettes

Montefiore Medical Center
NCT IDNCT05642715ClinicalTrials.gov data as of Apr 2026
Target enrollment

400

Study length

about 3 years

Ages

40–79

Locations

1 site in NY

About this study

This trial is testing whether a harm reduction strategy can help people with HIV who smoke cigarettes. The goal is to reduce the negative health effects associated with smoking in this population.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Participate in EX+
  • 2.Participate in HR
  • 3.Participate in TAU
  • +1 more
DrugVarenicline
Routeoral
Primary goalChange in systolic blood pressure (SBP)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low8%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

varenicline

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change in systolic blood pressure (SBP)

Secondary: Proportion of participants at target low dose low-density lipoprotein (LDL) cholesterol, Proportion of participants at target systolic blood pressure, Proportion with undetectable HIV-1 viral load

Body systems

Immune, Infectious